R. Nolan Townsend

R. Nolan Townsend

Chief Executive Officer and DirectoratLexeo Therapeutics· In proxies 2022–2025

Pay in FY2025-17% from the year before · Lexeo Therapeutics stock +50.9% the same year

R. Nolan Townsend was paid $3.7M in FY2025 (Dec), down 17%. Lexeo Therapeutics stock rose 50.9% that year.

Pay$100 in the stock at the end of FY23 → $74
Pay is from the Summary Compensation Table of each Lexeo Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lexeo TherapeuticsPublic company · 4 yr
    • Chief Executive Officer and Director2022 – Present · 4 yrStock in role -69%
  2. Arbor BiotechnologiesPublic company
    • Director? – PresentNo stock prices for these years
  3. Biotechnology Innovation OrganizationPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Lexeo TherapeuticsDirector · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?